Navigation Links
Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Company's Drug Development Pipeline
Date:5/29/2013

COLORADO SPRINGS, Colo., May 29, 2013 /PRNewswire/ -- Cannabis Science, Inc. (NASD OTC: CBIS), announced today the appointment of clinical development expert, Dr. Dorothy Bray , Ph.D., as Chief Executive Officer and Director.

Dr. Bray served as Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit in the UK.  She also held various positions of responsibility at GlaxoSmithKline as Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA, and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK and USA. 

"While it has been an honor and a privilege to hold the position of CEO in Cannabis Science during early development phase, the Company has grown dramatically and now requires a CEO with the experience and expertise that Dr. Bray unquestionably has. I am excited to remain as President and see her take the lead as the Company's new CEO. I think this strategic move will greatly accelerate our drug development program and bring CS-TATI-1 to the millions of HIV infected people around the world in need of this valuable addition to the world's pharmacopeia," said Dr. Robert Melamede , President and Director of Cannabis Science.

Dr. Bray is IMMUNOCLIN's founder, holds an honorary Senior Lecturer position at the Royal Free School of Medicine, University of London, and acts as the European Commission's Scientific Expert. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.  She has a track record of bringing scientific discoveries to market and acts as a business advisor to a number of biotechnology companies. 

Dr. Bray's extensive experience in the field of HIV drug development will lead Cannabis Science along with the prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitors. 

"Cannabis Science has an impressive team.  I am proud to be given the privilege of joining the Board and being asked to lead as Chief Executive Officer.  I look forward to working with the team and progressing to achieve the company goals set forth," stated Dr. Dorothy Bray , Ph.D., CEO & Director of Cannabis Science.

About CS-TATI-1
Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment-experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of Federal Research Programs such as RO1s, PO1s and SBIRs, which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid-based therapeutic research and development to address neglected pandemic oncological manifestations of pandemic infectious diseases in human health. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize other therapeutic approaches to antiviral and antibacterial innovation. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-TATI-1 topical cannabinoid-based preparations for the treatment of Kaposi's Sarcoma, basal and squamous cell carcinomas and HIV Tat inhibition.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Robert Kane
Vice President of Investor Relations
rkane@cannabisscience.com
561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
2. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
3. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
4. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
5. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
6. New Study Shows Cannabis Effects on Driving Skills
7. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
8. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
9. Cannabis Science Gets Set to Release "Phytiva" Its Newest Brand of Over-the-Counter Skin and Nutraceutical Product Lines Through its Newest Venture Phytiva Pharmaceuticals Inc.
10. Rapid Fire Marketing: CANNAcig to Sponsor Medical Cannabis Cup 2012 in San Francisco
11. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 2016 Story Highlights: ... within the health care industry is causing providers to ... , Deloitte offers a suite of solutions for health ... efficient cost optimization: labor resource analysis, revenue cycle optimization ... better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):